[1] 科技部十二五重大专项联合课题组专家. 乙型肝炎病毒相关肝硬化的临床诊断、评估和抗病毒治疗的综合管理. 中华肝脏病杂志, 2014,22:327-335.
[2] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015更新版). 中华肝脏病杂志, 2015,23:888-905.
[3] Xu K, Watanabe-Galloway S, Rochling FA, et al. Practice, Knowledge, and Barriers for Screening of Hepatocellular Carcinoma Among High-Risk Chinese Patients. Ann Glob Health, 2017,83:281-292.
[4] Tsai MC, Chen CH, Hu TH, et al. Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. J Formos Med Assoc, 2017,116:512-521.
[5] Ahn J, Lee HM, Lim JK, et al. Entecavir safety and effectiveness in a national cohort of treatment-na?ve chronic hepatitis B patients in the US - the ENUMERATE study. Aliment Pharmacol Ther, 2016,43:134-144.
[6] Baran B. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World J Hepatol, 2015,7:1742-1754.
[7] Wu IT, Hu TH, Hung CH, et al. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study. Clin Microbiol Infect, 2017,23:464-469.
[8] Wu Y, You S, Zang H, et al. Usefulness of serum thyroid-stimulation hormone (TSH) as a prognostic indicator for acute-on-chronic liver failure. Ann Hepatol, 2015,14:218-224. |
